Dipeptidyl peptidase (DPP)-4 is a complex enzyme that exists as a membrane-anchored cell surface peptidase that transmits intracellular signals via a short intracellular tail and as a second smaller ...

Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with ...

Context: Impairment of incretin activity is now recognized as integral to the metabolic derangement underlying type 2 diabetes. Glucoregulatory agents that target the incretin system have recently ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...

DPP-4 exists as both a membrane-bound and soluble form. DPP-4 has historically been associated with its capacity to metabolize incretin hormones. Recent studies have identified additional functions of ...

IB10 sphingotest® DPP3 is now available on sphingotec's proprietary automated Nexus IB10 point-of-care platform and quantitatively measures levels of circulating DPP3 in whole blood and plasma samples ...

It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin ...

bullous pemphigoid leg The relationship between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Regardless of the diagnosis of type 2 diabetes, patients with bullous ...

TACE combined with the intra-arterial infusion of bevacizumab for BCLC-stage B hepatocellular carcinoma beyond up-to-seven criteria: A prospective, single-arm, phase II study. Neoadjuvant ...